Describe current understanding of epidemiology, risk factors, pathobiology, societal costs, clinical differences, gaps in knowledge, and challenges in distinguishing and managing the spectra of normal cognitive aging, mild cognitive impairment (MCI), Alzheimer’s disease (AD), and other neurodegenerative dementias
Distinguish pre-clinical AD, MCI due to AD/prodromal AD, and AD dementia phases
Summarize tiered diagnostic and management approaches, and future experimental therapeutics strategies under consideration for risk reduction, prevention, diagnosis and treatment of the AD spectrum
Differentiate, based on neuropathology, affected neural systems, clinical criteria and biomarkers, AD and its atypical variants from other common dementias including Dementia with Lewy Bodies (DLB), Vascular Cognitive Impairment (VCI)/Vascular-Ischemic Dementia, Frontotemporal Degeneration (FTD), Parkinson’s disease with Dementia (PDD), Parkinson’s-Plus Syndromes and less common dementias
See course registration page for additional learning objectives
This is an accredited, livestreamed course offered by Brigham and Women's Hospital and Massachusetts General Hospital. This course is targeted to Primary Care Physicians, Specialty Physicians, Neuropsychologists, Nurses, Nurse Practitioners, Physician Assistants, Psychologists, and Social Workers. This course may also be of interest to physicians who practice in Family Medicine, Geriatrics, Hospice and Palliative Medicine, Internal Medicine, Lifestyle and Mind-Body Medicine, Medical Genetics and Genomics, Palliative Medicine, Physical Medicine & Rehab, Preventative medicine, Psychiatry and Neurology, Psychology and Mental Health.
Select the Take Course button to view additional information on the course registration page.
Contact ceprograms@hms.harvard.edu with questions.
